Baseline characteristics of patients included and not included in the analysis
| Characteristic . | Patients included (n = 307) . | Patients not included (n = 103) . | P . |
|---|---|---|---|
| Subgroup, N (%) | .58 | ||
| Men | 175 (57) | 56 (54) | |
| Women not taking estrogen | 83 (27) | 26 (25) | |
| Women taking estrogen | 49 (16) | 21 (21) | |
| Mean (SD) age, years | 52 (13) | 48 (16) | .01 |
| Mean (SD) weight, kg | 94 (24) | 90 (23) | .16 |
| Mean (SD) BMI, kg/m2 | 31 (7) | 30 (7) | .52 |
| Mean (SD) months on anticoagulation | 5 (1) | 5 (1) | .70 |
| Qualifying thrombotic event, N (%) | .003 | ||
| Proximal DVT only | 124 (40) | 59 (57) | |
| PE (with or without DVT) | 183 (60) | 44 (43) | |
| Risk factors for bleeding,*N (%) | .05 | ||
| None | 260 (85) | 95 (92) | |
| ≥1 | 47 (15) | 8 (8) | |
| Diabetes,† N (%) | 22 (7) | 8 (8) | .84 |
| Antiplatelet therapy,‡ N (%) | 22 (7) | 6 (6) | .65 |
| Statin therapy, N (%) | 54 (18) | 8 (8) | .02 |
| Family history of VTE,§ N (%) | 72 (23) | 16 (16) | .09 |
| Hyperpigmentation/edema of either leg, N (%) | 83 (27) | 17 (17) | .03 |
| Performance status,‖N (%) | .54 | ||
| Fully active | 277 (90) | 95 (92) | |
| Less than fully active | 30 (10) | 8 (8) |
| Characteristic . | Patients included (n = 307) . | Patients not included (n = 103) . | P . |
|---|---|---|---|
| Subgroup, N (%) | .58 | ||
| Men | 175 (57) | 56 (54) | |
| Women not taking estrogen | 83 (27) | 26 (25) | |
| Women taking estrogen | 49 (16) | 21 (21) | |
| Mean (SD) age, years | 52 (13) | 48 (16) | .01 |
| Mean (SD) weight, kg | 94 (24) | 90 (23) | .16 |
| Mean (SD) BMI, kg/m2 | 31 (7) | 30 (7) | .52 |
| Mean (SD) months on anticoagulation | 5 (1) | 5 (1) | .70 |
| Qualifying thrombotic event, N (%) | .003 | ||
| Proximal DVT only | 124 (40) | 59 (57) | |
| PE (with or without DVT) | 183 (60) | 44 (43) | |
| Risk factors for bleeding,*N (%) | .05 | ||
| None | 260 (85) | 95 (92) | |
| ≥1 | 47 (15) | 8 (8) | |
| Diabetes,† N (%) | 22 (7) | 8 (8) | .84 |
| Antiplatelet therapy,‡ N (%) | 22 (7) | 6 (6) | .65 |
| Statin therapy, N (%) | 54 (18) | 8 (8) | .02 |
| Family history of VTE,§ N (%) | 72 (23) | 16 (16) | .09 |
| Hyperpigmentation/edema of either leg, N (%) | 83 (27) | 17 (17) | .03 |
| Performance status,‖N (%) | .54 | ||
| Fully active | 277 (90) | 95 (92) | |
| Less than fully active | 30 (10) | 8 (8) |
BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.
Risk factors include: previous stroke, previous peptic ulcer disease, previous gastrointestinal bleeding, previous genitourinary bleeding, known gastrointestinal abnormality associated with bleeding, known genitourinary abnormality associated with bleeding, diabetes requiring medication, and antiplatelet therapy.
Requiring medication.
Aspirin in all patients.
One or more parents, siblings, or children.
Using Eastern Cooperative Oncology Group performance status and dichotomized as fully active (score, 0) vs less than fully active (score, 1-4).